FDA Advisory Committee finds efficiency of donanemab for Alzheimer’s treatment

BOWLING GREEN, Ky. – A drug is showing promising results for treating early Alzheimer’s disease, and the Alzheimer’s Association is hoping to make that treatment accessible.

The findings by the FDA advisory committee on Monday suggest the drug ‘donanemab’ is effective for the treatment of the early stages of the disease.

The drug would be the second traditional approval of an Alzheimer’s treatment that impacts the underlying course of the disease, by removing amyloid protein from the brain, to slow or even stop cognitive decline.

Executive director for the Greater Kentucky and Southern Indiana Chapter of the Alzheimer’s Association, Shannon White, says, “These new treatments are really giving our families so much hope and not everyone is eligible for these treatments, so we always encourage people to talk to your medical provider and if you think that you are seeing signs and symptoms of cognitive decline or something just isn’t right, you should talk to your medical professional to see if you are eligible for these drugs.”

The FDA has not yet approved this drug, but the Alzheimer’s Association has submitted comments to the advisory committee urging a traditional approval, in hopes of having this drug to patients in just a few weeks.